Fierce Pharma Asia—Roche’s $2.5B obesity deal; Akeso CEO’s defense; Lawmaker’s reflection on China

With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over shrinking lung cancer data for ivonescimab. A U.S. congressman says China is "beating us on our ground game" in biotech. Plus more.